Solara Active Pharma Sciences profit and loss

Latest FY26

Revenue: ₹1,369cr+6.6% on FY25
EBITDA: ₹187cr−9.5% on FY25
Net profit: −₹7.4cr₹0.5 cr in FY25
EPS: −₹1.68₹0.14 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	1,535	1,369	1,284	1,289	1,444	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	7.9	6.2	8.3	5.4	22.6
	1,543	1,375	1,292	1,294	1,466
	757	673	582	761	774
	6.7	3.5	5.8	5.1	7.9
	30.9	8.3	39.0	39.3	7.1
	224	219	212	244	229
	89.4	94.8	115	105	90.1
	105	99.7	99.3	103	111
	283	279	239	335	292
	1,496	1,377	1,292	1,593	1,511
	234	187	206	−95.2	134
	129	87.1	107	−199	22.7
Profit
	47.3	−1.5	0.5	−298	−44.8
	−10.4	−5.9	0.0	−190	0.0
	36.9	−7.4	0.5	−488	−44.8
	0.0	0.0	0.0	0.0	−0.1
	0.0	0.0	0.0	78.5	−22.5
	0.0	0.0	0.0	78.5	−22.6
	36.9	−7.4	0.5	−567	−22.2
	36.9	−7.4	0.5	−567	−22.2
	2.1	2.9	1.0	0.5	−2.1
	39.1	−4.6	1.5	−566	−24.3
	36.9	−7.4	0.5	−567	−22.2
	0.0	0.0	−0.0	0.4	−0.1
Per share
	₹7.66	−₹1.68	₹0.14	−₹157.62	−₹6.16
	₹7.66	−₹1.68	₹0.14	−₹157.62	−₹6.16
Other comprehensive income — detail
	2.1	2.9	1.0	—	—
	—	3.3	1.1	0.6	−2.7
	—	—	—	0.0	−0.9
	−0.3	−0.4	−0.1	−0.1	−0.3
	39.1	−4.6	1.0	−567	−24.2
	0.0	0.0	0.0	0.4	−0.1
Per share — as-filed variants
	₹7.66	−₹1.68	₹0.14	−₹157.62	−₹6.16
	₹7.66	−₹1.68	₹0.14	−₹157.62	−₹6.16
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	741	684	657	484	655
	48.3%	50.0%	51.2%	37.5%	45.4%
Adjusted (ex-exceptional items) — derived
	47.3	−1.5	0.5	−298	−44.8
	−10.4	−5.9	0.0	−190	0.0
	47.3	−1.5	0.5	−377	−22.2
	₹9.81	−₹0.34	₹0.14	−₹104.75	−₹6.16

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersINDSWFTLAB DCAL SMSPHARMA HIKAL PANACEABIO SAIPARENT INDOCO UNICHEMLABMcap ₹2,910 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,443.8	1,288.9	1,283.8	1,369.0	1,535.2
Other Income	22.6	5.4	8.3	6.2	7.9
Total Income	1,466.4	1,294.3	1,292.1	1,375.1	1,543.2
Expenses
+ Cost of Materials Consumed	773.9	760.7	581.7	672.8	756.6
+ Purchases of Stock-in-Trade	7.9	5.1	5.8	3.5	6.7
+ Changes in Inventories	7.1	39.3	39.0	8.3	30.9
+ Employee Benefit Expense	228.6	243.9	211.7	219.2	224.4
+ Finance Costs	90.1	105.1	114.8	94.8	89.4
+ Depreciation & Amortisation	111.2	103.3	99.3	99.7	105.0
+ Other Expenses	292.5	335.2	239.4	278.5	282.9
Total Expenses	1,511.2	1,592.5	1,291.5	1,376.7	1,495.8
EBITDA	133.9	-95.2	206.3	186.8	233.8
EBIT	22.7	-198.5	107.0	87.1	128.9
Profit
PBT before Exceptional Items	-44.8	-298.3	0.5	-1.5	47.3
+ Exceptional Items	0.0	-190.2	0.0	-5.9	-10.4
Pretax Income	-44.8	-488.4	0.5	-7.4	36.9
+ Current Tax	-0.1	0.0	0.0	0.0	0.0
+ Deferred Tax	-22.5	78.5	0.0	0.0	0.0
Tax Expense	-22.6	78.5	0.0	0.0	0.0
Net Income	-22.2	-567.0	0.5	-7.4	36.9
+ Net Income — Continuing Ops	-22.2	-567.0	0.5	-7.4	36.9
+ Other Comprehensive Income	-2.1	0.5	1.0	2.9	2.1
Total Comprehensive Income	-24.3	-566.5	1.5	-4.6	39.1
Net Income to Common	-22.2	-567.4	0.5	-7.4	36.9
Minority Interest	-0.1	0.4	-0.0	0.0	0.0
Per Share
Basic EPS	-6.16	-157.62	0.14	-1.68	7.66
Diluted EPS	-6.16	-157.62	0.14	-1.68	7.66
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	1.0	2.9	2.1
+ Items NOT to be Reclassified to P&L	-2.7	0.6	1.1	3.3	—
+ Tax on Items NOT to be Reclassified — alt tag	-0.9	0.0	—	—	—
+ Items to be Reclassified to P&L	-0.3	-0.1	-0.1	-0.4	-0.3
Comprehensive Income — Owners of Parent	-24.2	-566.9	1.0	-4.6	39.1
Comprehensive Income — Non-controlling Interests	-0.1	0.4	0.0	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	-6.16	-157.62	0.14	-1.68	7.66
Diluted EPS — Continuing Operations	-6.16	-157.62	0.14	-1.68	7.66
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	655.0	483.9	657.4	684.5	741.1
Gross Margin %	45.37	37.54	51.21	50.00	48.27
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-44.8	-298.3	0.5	-1.5	47.3
− Exceptional Items (reconciliation)	0.0	-190.2	0.0	-5.9	-10.4
Net Income Adj (tax-effected)	-22.2	-376.8	0.5	-1.5	47.3
EPS Adj	-6.16	-104.75	0.14	-0.34	9.81
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	36.0	36.0	40.3	44.5	48.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.